Literature DB >> 25082979

NLRP7 inter-domain interactions: the NACHT-associated domain is the physical mediator for oligomeric assembly.

Heike Singer1, Arijit Biswas1, Nicole Zimmer1, Christiane Messaed2, Johannes Oldenburg1, Rima Slim2, Osman El-Maarri3.   

Abstract

Mutations in NLRP7 (NOD-like-receptor family, pyrin domain containing 7) are responsible for a type of recurrent pregnancy loss known as recurrent hydatidiform mole (HYDM1). This condition is characterized by abnormal growth of the placenta, a lack of proper embryonic development and abnormal methylation patterns at multiple imprinted loci in diploid biparental molar tissues. The role of NLRP7 protein in the disease manifestation is currently not clear. In order to better understand how the effects of HYDM1 are associated with mutations on the structure of NLRP7, we performed an inter-domain interaction screen using a yeast two-hybrid system. Additionally, we generated in silico structural models of NLRP7 in its non-activated and activated forms. Our observations from the yeast two-hybrid screen and modeling suggest that the NACHT-associated domain (NAD) of the NLRP7 protein is central to its oligomeric assembly. Upon activation, the NAD and a small part of the leucine rich repeat (LRR) of one molecule emerged out of the protective LRR domain and interact with the NACHT domain of the second molecule to form an oligomer. Furthermore, we investigated the molecular basis for the pathophysiological effect of four missense mutations, three HYDM1-causing and one rare non-synonymous variant, on the protein using confocal microscopy of transiently transfected NLRP7 in HEK293T cells and in silico structural analysis. We found that with the two clinically severe missense mutations, L398R and R693W, the normal molecule to molecule interaction was apparently affected thus decreasing their oligomerization potential while aggresome formation was increased; these changes could disturb the normal downstream functions of NLRP7 and therefore be a possible molecular effect underlying their pathophysiological impact.
© The Author 2014. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  HYDM1-causing mutations; NLRP7; aggresome; inter-domain-interactions; protein misfolding

Mesh:

Substances:

Year:  2014        PMID: 25082979      PMCID: PMC4172174          DOI: 10.1093/molehr/gau060

Source DB:  PubMed          Journal:  Mol Hum Reprod        ISSN: 1360-9947            Impact factor:   4.025


  45 in total

1.  Increasing the precision of comparative models with YASARA NOVA--a self-parameterizing force field.

Authors:  Elmar Krieger; Günther Koraimann; Gert Vriend
Journal:  Proteins       Date:  2002-05-15

2.  Three-dimensional structure of the NLRP7 pyrin domain: insight into pyrin-pyrin-mediated effector domain signaling in innate immunity.

Authors:  Anderson S Pinheiro; Martina Proell; Clarissa Eibl; Rebecca Page; Robert Schwarzenbacher; Wolfgang Peti
Journal:  J Biol Chem       Date:  2010-06-11       Impact factor: 5.157

Review 3.  Familial hydatidiform molar pregnancy: the germline imprinting defect hypothesis?

Authors:  O El-Maarri; R Slim
Journal:  Curr Top Microbiol Immunol       Date:  2006       Impact factor: 4.291

4.  A recurrent intragenic genomic duplication, other novel mutations in NLRP7 and imprinting defects in recurrent biparental hydatidiform moles.

Authors:  Y C Kou; L Shao; H H Peng; R Rosetta; D del Gaudio; A F Wagner; T K Al-Hussaini; I B Van den Veyver
Journal:  Mol Hum Reprod       Date:  2007-11-26       Impact factor: 4.025

Review 5.  Wheel of Life, Wheel of Death: A Mechanistic Insight into Signaling by STAND Proteins.

Authors:  Olivier Danot; Emélie Marquenet; Dominique Vidal-Ingigliardi; Evelyne Richet
Journal:  Structure       Date:  2009-02-13       Impact factor: 5.006

6.  A graphical interface for the FoldX forcefield.

Authors:  Joost Van Durme; Javier Delgado; Francois Stricher; Luis Serrano; Joost Schymkowitz; Frederic Rousseau
Journal:  Bioinformatics       Date:  2011-04-19       Impact factor: 6.937

7.  Mater, a maternal effect gene required for early embryonic development in mice.

Authors:  Z B Tong; L Gold; K E Pfeifer; H Dorward; E Lee; C A Bondy; J Dean; L M Nelson
Journal:  Nat Genet       Date:  2000-11       Impact factor: 38.330

8.  Cryopyrin/NALP3 binds ATP/dATP, is an ATPase, and requires ATP binding to mediate inflammatory signaling.

Authors:  Joseph A Duncan; Daniel T Bergstralh; Yanhong Wang; Stephen B Willingham; Zhengmao Ye; Albert G Zimmermann; Jenny Pan-Yun Ting
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-02       Impact factor: 11.205

9.  Mutations in NALP7 cause recurrent hydatidiform moles and reproductive wastage in humans.

Authors:  Sharlene Murdoch; Ugljesa Djuric; Batool Mazhar; Muheiddine Seoud; Rabia Khan; Rork Kuick; Rashmi Bagga; Renate Kircheisen; Asangla Ao; Bhawna Ratti; Samir Hanash; Guy A Rouleau; Rima Slim
Journal:  Nat Genet       Date:  2006-02-05       Impact factor: 38.330

10.  Aggresomes: a cellular response to misfolded proteins.

Authors:  J A Johnston; C L Ward; R R Kopito
Journal:  J Cell Biol       Date:  1998-12-28       Impact factor: 10.539

View more
  12 in total

1.  ATP binding by NLRP7 is required for inflammasome activation in response to bacterial lipopeptides.

Authors:  Alexander D Radian; Sonal Khare; Lan H Chu; Andrea Dorfleutner; Christian Stehlik
Journal:  Mol Immunol       Date:  2015-07-02       Impact factor: 4.407

Review 2.  Inflammasome activation and regulation: toward a better understanding of complex mechanisms.

Authors:  Danping Zheng; Timur Liwinski; Eran Elinav
Journal:  Cell Discov       Date:  2020-06-09       Impact factor: 10.849

3.  NLRP7 variants in spontaneous abortions with multilocus imprinting disturbances from women with recurrent pregnancy loss.

Authors:  Elena A Sazhenova; Tatyana V Nikitina; Stanislav A Vasilyev; Ekaterina N Tolmacheva; Oksana Yu Vasilyeva; Anton V Markov; Sergey Yu Yuryev; Nikolay A Skryabin; Alexey A Zarubin; Nikita A Kolesnikov; Vadim A Stepanov; Igor N Lebedev
Journal:  J Assist Reprod Genet       Date:  2021-09-23       Impact factor: 3.412

4.  Abnormal processing of IL-1β in NLRP7-mutated monocytes in hydatidiform mole patients.

Authors:  P Zhang; X Zhu; X Yu; B Huang; T Jiang; X Zhang; H Yang; J Qian
Journal:  Clin Exp Immunol       Date:  2020-07-06       Impact factor: 4.330

5.  NLRP7, Involved in Hydatidiform Molar Pregnancy (HYDM1), Interacts with the Transcriptional Repressor ZBTB16.

Authors:  Heike Singer; Arijit Biswas; Nicole Nuesgen; Johannes Oldenburg; Osman El-Maarri
Journal:  PLoS One       Date:  2015-06-29       Impact factor: 3.240

6.  NLRP7 contributes to in vitro decidualization of endometrial stromal cells.

Authors:  Jyun-Yuan Huang; Pei-Hsiu Yu; Yueh-Chun Li; Pao-Lin Kuo
Journal:  Reprod Biol Endocrinol       Date:  2017-08-15       Impact factor: 5.211

7.  Targeting the deubiquitinase STAMBP inhibits NALP7 inflammasome activity.

Authors:  Joseph S Bednash; Nathaniel Weathington; James Londino; Mauricio Rojas; Dexter L Gulick; Robert Fort; SeungHye Han; Alison C McKelvey; Bill B Chen; Rama K Mallampalli
Journal:  Nat Commun       Date:  2017-05-11       Impact factor: 14.919

Review 8.  The classification, genetic diagnosis and modelling of monogenic autoinflammatory disorders.

Authors:  Fiona Moghaddas; Seth L Masters
Journal:  Clin Sci (Lond)       Date:  2018-09-05       Impact factor: 6.124

9.  A Novel Mutation in NLRP7 Related to Recurrent Hydatidiform Mole and Reproductive Failure.

Authors:  Jafar Fallahi; Vahid Razban; Mozhdeh Momtahan; Mojgan Akbarzadeh-Jahromi; Bahia Namavar-Jahromi; Zahra Anvar; Majid Fardaei
Journal:  Int J Fertil Steril       Date:  2019-04-27

Review 10.  Inflammasome activation and regulation: toward a better understanding of complex mechanisms.

Authors:  Danping Zheng; Timur Liwinski; Eran Elinav
Journal:  Cell Discov       Date:  2020-06-09       Impact factor: 10.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.